Vita Life Sciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Vita Life Sciences için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	54.6%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Vita Life Sciences yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

ASX:VLS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	79	9	10	11	N/A
3/31/2024	77	9	11	12	N/A
12/31/2023	74	9	12	13	N/A
9/30/2023	71	8	10	10	N/A
6/30/2023	69	7	7	7	N/A
3/31/2023	68	7	5	5	N/A
12/31/2022	67	7	3	3	N/A
9/30/2022	65	8	2	2	N/A
6/30/2022	64	8	1	2	N/A
3/31/2022	61	8	4	4	N/A
12/31/2021	57	8	6	6	N/A
9/30/2021	54	8	6	6	N/A
6/30/2021	50	7	7	7	N/A
3/31/2021	48	6	7	7	N/A
12/31/2020	46	6	7	8	N/A
9/30/2020	46	6	7	7	N/A
6/30/2020	45	5	7	7	N/A
3/31/2020	44	4	5	5	N/A
12/31/2019	42	3	2	2	N/A
9/30/2019	42	2	2	2	N/A
6/30/2019	41	2	2	2	N/A
3/31/2019	41	2	3	3	N/A
12/31/2018	41	2	4	4	N/A
9/30/2018	40	3	N/A	N/A	N/A
6/30/2018	40	4	4	5	N/A
3/31/2018	38	3	N/A	4	N/A
12/31/2017	37	3	N/A	3	N/A
9/30/2017	37	3	N/A	N/A	N/A
6/30/2017	37	3	N/A	4	N/A
3/31/2017	38	3	N/A	5	N/A
12/31/2016	38	3	N/A	5	N/A
9/30/2016	38	4	N/A	4	N/A
6/30/2016	38	5	N/A	3	N/A
3/31/2016	39	5	N/A	4	N/A
12/31/2015	39	4	N/A	5	N/A
9/30/2015	38	4	N/A	6	N/A
6/30/2015	37	4	N/A	6	N/A
3/31/2015	37	6	N/A	6	N/A
12/31/2014	37	7	N/A	6	N/A
9/30/2014	36	7	N/A	6	N/A
6/30/2014	36	7	N/A	5	N/A
3/31/2014	36	6	N/A	5	N/A
12/31/2013	35	5	N/A	5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VLS 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.4% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: VLS 'un kazançlarının Australian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: VLS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: VLS şirketinin gelirinin Australian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: VLS şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VLS 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Vita Life Sciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Recent updates

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Upcoming Dividend of AU$0.015 Per Share

New 90-day high - AU$0.95

First half earnings released

New 90-day high - AU$0.70

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin